The present report discusses the clinical indications that can support the administration of deferoxamine for iron intoxication in pregnancy and discusses the benefits and risks of its usage. [ncbi.nlm.nih.gov]

• Localized Pain

  pain, irritation, burning, swelling, and induration may occur at the injection site following IV or sub-Q administration. 118 b Adverse ocular and otic effects (see Warnings), abdominal discomfort, diarrhea, nausea, vomiting, leg cramps, tachycardia, [web.archive.org]

• Gangrene

  A 49-year-old woman undergoing long-term hemodialysis and treated with deferoxamine (DFO) 1.5 g twice weekly for aluminum bone disease developed fever and bilateral calf pain caused by myonecrosis with gas gangrene. She had a rapidly fatal outcome. [ncbi.nlm.nih.gov]

• Gagging

  The release of hypoxia related reparative factors by the cells on the collagen-GAG substrate was evaluated to detect if DFO produces results comparable to environmentally induced hypoxia to facilitate optimal clinical settings. [ncbi.nlm.nih.gov]

• Intestinal Perforation

  Despite the frequency of gastrointestinal disease caused by Yersinia enterocolitica, intestinal perforation is a rare complication of this infection and to date only eight cases have been reported in the English literature. [ncbi.nlm.nih.gov]

• Left Ventricular Dysfunction

  Deferoxamine is effective in chelating non-transferrin bound iron and can reverse cardiac arrhythmias and left-ventricular dysfunction, although, combination chelation therapy is usually recommended for patients with cardiac dysfunction. [thalassemia.com]

  Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med. 1983; 99:450-4. [IDIS 176699] [PubMed 6625375] 102. Marcus RE, Davies SC, Bantock HM et al. [web.archive.org]

  Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med. 1983; 99:450-4. http://www.ncbi.nlm.nih.gov/pubmed/6625375?dopt=AbstractPlus 102. Marcus RE, Davies SC, Bantock HM et al. [drugs.com]

• Periodontitis

  The purpose of the present study was to investigate the influence of DFO on the proliferation, migration and osteogenic differentiation of human periodontal ligament cells (hPDLCs). [ncbi.nlm.nih.gov]

• Calf Pain

  A 49-year-old woman undergoing long-term hemodialysis and treated with deferoxamine (DFO) 1.5 g twice weekly for aluminum bone disease developed fever and bilateral calf pain caused by myonecrosis with gas gangrene. She had a rapidly fatal outcome. [ncbi.nlm.nih.gov]

• Intracranial Hemorrhage

  Deferoxamine is also used to minimize doxorubicin 's cardiotoxic side effects and in the treatment of a patient with aceruloplasminemia. [9] Deferoxamine maybe effective for improving neurologic outcomes in persons with intracranial hemorrhage, although [en.wikipedia.org]

• Myoclonus

  We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate. [ncbi.nlm.nih.gov]

• Meningism

  The model comprises a co-culture system of cerebral astrocytes and meningeal fibroblasts, which form scar-like clusters when stimulated with transforming growth factor-β (TGF-β). [ncbi.nlm.nih.gov]

• Oliguria

  If oliguria or anuria develop, dialysis may be required. References… Bailey, B., Blais, R., Gaudreault, P., Gosselin, S., & Laliberte, M. (2009). Antidotes en toxicologie d'urgence (3rd ed.). Quebec, Canada: Centre antipoison du Quebec. [iwkpoisoncentre.ca]

  If oliguria or anuria develop, peritoneal dialysis or hemodialysis may become necessary to remove the ferrioxamine. [rxmed.com]

• Vitamin C Increased

  Ascorbic acid (vitamin C) increases the excretion of iron in the presence of deferoxamine. It is started after the initial month of deferoxamine therapy. [thalassemia.com]

Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients. [ncbi.nlm.nih.gov]

Studies in acute iron poisoning 11: desferrioxamine in the treatment of acute iron poisoning. Further observations of desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics. 1966; 38:102-10. [PubMed 5937669] 176. [web.archive.org]

The frequent lack of early diagnosis, itself subsequent to a break away from the standard diagnostic tools (apart from biopsy and culture) makes the survival prognosis particularly critical. [ncbi.nlm.nih.gov]

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. [karger.com]

View Article PubMed Google Scholar Larose E, Ganz P, Reynolds HG, Dorbala S, Di Carli MF, Brown KA, Kwong RY: Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. [jcmr-online.biomedcentral.com]

Pharmacosurveillance and quality of care of thalassaemic patients: a large scale epidemiological survey. Eur J Clin Pharmacol. 2001 ; 56 : 915 -922. [bloodjournal.org]

Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86: 480-487. PubMed: 18568278. View Article Google Scholar 3. [journals.plos.org]

We hypothesize that this elevation in CSF aluminum may account for the observed neurologic deterioration after deferoxamine and postulate various pathophysiologic mechanisms that might be involved. [ncbi.nlm.nih.gov]

Modell, “The Pathophysiology of Beta-Thalassaemia Major,” Journal of Clinical Pathology. Supplement (Royal College of Pathologists), Vol. 8, 1974, pp. 12-18. [ 31 ] A. [scirp.org]

Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80 : 617. ↵ Weinberg, E. D.. 1989. Iron, asbestos, and carcinogenicity. Lancet 1 : 1399. ↵ Nemeth, Z. H., E. A. Deitch, C. Szabo, Z. Fekete, C. J. Hauser, G. Hasko. 2002. [jimmunol.org]

Both L1 and DF could also prevent iron absorption. The new oral chelator deferasirox (DFX) increases iron excretion and decreases liver iron in TM and TI. [ncbi.nlm.nih.gov]

Researchers plan to continue studying patients receiving deferoxamine as treatment for the prevention of heart complications associated with repeated blood transfusions. [clinicaltrials.gov]

Both L 1 and DF could also prevent iron absorption. The new oral chelator deferasirox (DFX) increases iron excretion and decreases liver iron in TM and TI. [dovepress.com]